XM does not provide services to residents of the United States of America.
I
I

IQVIA


News

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
A
C
E
I
K
R
A
A
E
G
U
A
A
A
I

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
C
E
I
K
R
U
A
A
S
E
G
U
I

IQVIA Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary

IQVIA Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.84​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $2.49. The mean expectation of twenty one analysts for the quarter was for earnings of $2.81 per share.
I

What to Watch in the Day Ahead - Friday, November 1

What to Watch in the Day Ahead - Friday, November 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT On the U.S. economic front, the Labor Department's monthly employment report is expected to show that nonfarm payrolls likely added 113,000 jobs in October after adding 254,000 jobs in September.
A
C
C
D
C
I

U.S. STOCKS Estee Lauder, DoorDash, Peloton Interactive

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, DoorDash, Peloton Interactive Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Thursday, as warnings from Microsoft and Meta Platforms about soaring AI costs dampened enthusiasm for megacap stocks, which have led the market this year.
A
B
C
C
E
I
M
R
W
X
S
U
U
E
E
P
U
H
I
T

IQVIA lowers annual revenue forecast amid trial delays

UPDATE 1-IQVIA lowers annual revenue forecast amid trial delays Adds details on earnings throughout, shares in paragraph 2, executive comments in paragraphs 8-9 By Puyaan Singh Oct 31 (Reuters) - Contract research firm IQVIA IQV.N lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.
I

IQVIA falls on forecast cut due to delay of two 'mega-trials'

BUZZ-IQVIA falls on forecast cut due to delay of two 'mega-trials' Updates ** Shares of contract research firm IQVIA holdings IQV.N f all as much as 7.3% to $200.3; hitting lowest levels since November last year ** Com pany sees 2024 revenue to be between $15.35 bln and $15.4 bln vs range of $15.43 bln to $15.53 bln previously expected ** IQV says
I

IQVIA falls on forecast cut due to delay of two 'mega-trials'

BUZZ-IQVIA falls on forecast cut due to delay of two 'mega-trials' ** Shares of contract research firm IQVIA holdings IQV.N decline about 9% to $197 premarket ** Co sees 2024 revenue to be between $15.35 bln and $15.4 bln vs prior range of $15.43 bln to $15.53 bln previously expected ** IQV says lowering outlook to "reflect delays in two fast-burni
I

IQVIA lowers annual revenue forecast due to delays in two clinical trials

REFILE-IQVIA lowers annual revenue forecast due to delays in two clinical trials Corrects to add story keyword used by media customers, no changes to text Oct 31 (Reuters) - Contract research firm IQVIA Holdings IQV.N lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges, sending the company's shares down 7% in premarket trade.
I

Iqvia Reports Third-Quarter 2024 Results And Announces Investor Day

BRIEF-Iqvia Reports Third-Quarter 2024 Results And Announces Investor Day Oct 31 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA REPORTS THIRD-QUARTER 2024 RESULTS AND ANNOUNCES INVESTOR DAY Source text: ID:nBw1tMFLZa Further company coverage: IQV.N
I

IQVIA Q3 Adjusted EPS USD 2.84 Vs. IBES Estimate USD 2.81

BRIEF-IQVIA Q3 Adjusted EPS USD 2.84 Vs. IBES Estimate USD 2.81 Oct 31 (Reuters) - IQVIA Q3 revenue USD 3,896 million vs. IBES estimate USD 3,857 million. Q3 net income USD 285 million Q3 adjusted EBITDA USD 939 million vs. IBES estimate USD 938.1 million Q3 EPS USD 1.55 outlook FY adjusted EPS USD 11.1-11.2 outlook FY adjusted EBITDA USD 3,675-3,7
I

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Tesla Inc TSLA.OQ +21.8% Molina Healthcare Inc MOH.N +18.8% West Pharmaceutical Services Inc WST.N +15.3% CBRE Group Inc CBRE.N +8.5% Raymond James Financial Inc RJF.N +7.2% Bottom Performers Percent Change Newmont Corporation NEM.N -1
T
T
U
C
I
R
T

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Molina Healthcare Inc MOH.N +23.8% Tesla Inc TSLA.OQ +18.9% West Pharmaceutical Services Inc WST.N +18.1% CBRE Group Inc CBRE.N +9.3% Align Technology Inc ALGN.OQ +7.7% Bottom Performers Percent Change Newmont Corporation NEM.N -11.4%
T
T
U
A
C
I
T

U.S. BXP, Medpace Holdings, Starbucks

U.S. RESEARCH ROUNDUP-BXP, Medpace Holdings, Starbucks Oct 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including BXP, Medpace Holdings and Starbucks, on Wednesday. HIGHLIGHTS * BXP Inc BXP.N : Piper Sandler raises to overweight from neutral * Danaher Corp DHR.N : TD Cowen raises target price to $315 from $310 * Medpace Holdings Inc MEDP.O : Jefferies cuts target price to $305 from $345 * Starbucks SBUX.O : Stifel cuts ta
I
M
P
S
Z
S
G
I

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals

UPDATE 1-Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals Adds comments from Jennifer Fleury in paragraph 6 By David Thomas Oct 15 (Reuters) - International law firm Hogan Lovells said on Tuesday that it has hired a senior lawyer from the U.S. Federal Trade Commission amid a period of increased antitrust enforcement activity by the agency.
M
I

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals By David Thomas Oct 15 (Reuters) - International law firm Hogan Lovells said on Tuesday that it has hired a senior lawyer from the U.S. Federal Trade Commission amid a period of increased antitrust enforcement activity by the agency. Jennifer Fleury joined Hogan Lovells as a partner in its Washington, D.C.
M
I

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P

India's Strides Pharma rises on US FDA nod for drug to treat asthma, lung diseases

BUZZ-India's Strides Pharma rises on US FDA nod for drug to treat asthma, lung diseases ** Shares of Strides Pharma Science SRID.NS rise 2.4% to 1,376.8 rupees ** The pharma products maker's unit gets approval from U.S. Food and Drug Administration for generic version of a drug used to treat chronic asthma and lung diseases like emphysema and bronchitis ** The drug - Theophylline extended-release tablet - has a market size of $11.5 million, as per pharma analytics and research firm IQVIA ** SRID
I



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.